CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi
Cancer Research and Treatment. 2018;50(2):398-404.   Published online 2017 May 10    DOI: https://doi.org/10.4143/crt.2017.074

Excel Download

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Cancer Research and Treatment. 2018;50(2):398-404   Crossref logo
Link1 Link2 Link3

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
Investigational New Drugs. 2017;35(5):634-641   Crossref logo
Link1 Link2 Link3

Photodynamic therapy of non-resectable cholangio carcinoma — A randomized prospective study — First results
Gastrointestinal Endoscopy. 2001;53(5):AB85   Crossref logo
Link1 Link2

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
Investigational New Drugs. 2017;35(2):235-241   Crossref logo
Link1 Link2 Link3

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Yearbook of Oncology. 2010;2010:26-27   Crossref logo
Link1 Link2

Dysport® for the treatment of myofascial back pain: Results from an open-label, Phase II, randomized, multicenter, dose-ranging study
Scandinavian Journal of Pain. 2017;2(1):25-33   Crossref logo
Link1 Link2 Link3 Link4

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Journal of Hepatology. 2012;56(2):486-487   Crossref logo
Link1 Link2

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2013;14(1):19-27   Crossref logo
Link1 Link2

Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study
Journal of Thoracic Oncology. 2009;4(12):1530-1536   Crossref logo
Link1 Link2

2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study
European Journal of Cancer. 2015;51:S380-S381   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.